| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, 30625 Hannover, Germany
The catalytic component of human telomerase reverse transcriptase (hTERT) is not expressed in most primary somatic human cells, whereas the majority of cancer cells reactivate telomerase by transcriptional up-regulation of hTERT. Several studies demonstrated that the hTERT promoter can be used to restrict gene expression of E1-deleted replication defective adenoviral vectors to telomerase-positive cancer cells. In this study, a conditionally replicating adenovirus (hTERT-Ad) expressing E1A genes under control of a 255-bp hTERT-promoter was constructed. Additionally, an internal ribosomal entry site-enhanced green fluorescent protein cassette was inserted downstream of the E1B locus to monitor viral replication in vivo. Adenoviral replication of hTERT-Ad and enhancement of enhanced green fluorescent protein expression could be observed in all investigated telomerase-positive tumor cell lines. In contrast, hTERT-Ad infection of telomerase-negative primary human hepatocytes did not result in significant replication. The capability of hTERT-Ad to induce cytopathic effects in tumor cells was comparable with that of adenovirus wild type and significantly higher compared with ONYX-015, regardless of the p53 status of the tumor cells. Single application of low-dose hTERT-Ad to tumor xenografts led to significant inhibition of tumor growth, confirming the potential therapeutic value of conditionally replicative adenoviral vectors. These in vivo experiments also revealed that hTERT-Ad-mediated oncolysis was more efficient than ONYX-015 treatment. These results demonstrate that expression of E1A under transcriptional control of the hTERT promoter is sufficient for effective telomerase-dependent adenovirus replication as a promising perspective for the treatment of the majority of epithelial tumors.
This article has been cited by other articles:
|
|
 |
|
  C. Su, M. Na, J. Chen, X. Wang, Y. Liu, W. Wang, Q. Zhang, L. Li, J. Long, X. Liu, et al. Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy Mol. Cancer Res., April 1, 2008; 6(4): 568 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Leja, H. Dzojic, E. Gustafson, K. Oberg, V. Giandomenico, and M. Essand A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy Clin. Cancer Res., April 15, 2007; 13(8): 2455 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhang, G. Chen, L. Peng, X. Wang, Y. Yang, C. Liu, W. Shi, C. Su, H. Wu, X. Liu, et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin. Cancer Res., November 1, 2006; 12(21): 6523 - 6531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hoffmann and O. Wildner Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. Mol. Cancer Ther., August 1, 2006; 5(8): 2013 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ito, H. Aoki, F. Kuhnel, Y. Kondo, S. Kubicka, T. Wirth, E. Iwado, A. Iwamaru, K. Fujiwara, K. R. Hess, et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst, May 3, 2006; 98(9): 625 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Le, H. N. Le, I. P. Dmitriev, J. G. Davydova, T. Gavrikova, S. Yamamoto, D. T. Curiel, and M. Yamamoto Dynamic Monitoring of Oncolytic Adenovirus In Vivo by Genetic Capsid Labeling J Natl Cancer Inst, February 1, 2006; 98(3): 203 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Fisher Is mda-7/IL-24 a "Magic Bullet" for Cancer? Cancer Res., November 15, 2005; 65(22): 10128 - 10138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wirth, F. Kuhnel, B. Fleischmann-Mundt, N. Woller, M. Djojosubroto, K. L. Rudolph, M. Manns, L. Zender, and S. Kubicka Telomerase-Dependent Virotherapy Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand by Elimination of Mcl-1 Cancer Res., August 15, 2005; 65(16): 7393 - 7402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kamizono, S. Nagano, Y. Murofushi, S. Komiya, H. Fujiwara, T. Matsuishi, and K.-i. Kosai Survivin-Responsive Conditionally Replicating Adenovirus Exhibits Cancer-Specific and Efficient Viral Replication Cancer Res., June 15, 2005; 65(12): 5284 - 5291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhu, J. A. Bristol, Y. Xie, M. Mina, H. Ji, S. Forry-Schaudies, and D. L. Ennist Linked Tumor-Selective Virus Replication and Transgene Expression from E3-Containing Oncolytic Adenoviruses J. Virol., May 1, 2005; 79(9): 5455 - 5465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kuhnel, B. Schulte, T. Wirth, N. Woller, S. Schafers, L. Zender, M. Manns, and S. Kubicka Protein Transduction Domains Fused to Virus Receptors Improve Cellular Virus Uptake and Enhance Oncolysis by Tumor-Specific Replicating Vectors J. Virol., December 15, 2004; 78(24): 13743 - 13754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biroccio and C. Leonetti Telomerase as a new target for the treatment of hormone-refractory prostate cancer Endocr. Relat. Cancer, September 1, 2004; 11(3): 407 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhang, M. Nie, J. Sham, C. Su, H. Xue, D. Chua, W. Wang, Z. Cui, Y. Liu, C. Liu, et al. Effective Gene-Viral Therapy for Telomerase-Positive Cancers by Selective Replicative-Competent Adenovirus Combining with Endostatin Gene Cancer Res., August 1, 2004; 64(15): 5390 - 5397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Groot-Wassink, E. O. Aboagye, Y. Wang, N. R. Lemoine, W. N. Keith, and G. Vassaux Noninvasive Imaging of the Transcriptional Activities of Human Telomerase Promoter Fragments in Mice Cancer Res., July 15, 2004; 64(14): 4906 - 4911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Toth, H. Djeha, B. Ying, A. E. Tollefson, M. Kuppuswamy, K. Doronin, P. Krajcsi, K. Lipinski, C. J. Wrighton, and W. S. M. Wold An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cell Spreading, Mediated by the ADP Cytolytic Protein, with Selective Replication in Cancer Cells with Deregulated Wnt Signaling Cancer Res., May 15, 2004; 64(10): 3638 - 3644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kawashima, S. Kagawa, N. Kobayashi, Y. Shirakiya, T. Umeoka, F. Teraishi, M. Taki, S. Kyo, N. Tanaka, and T. Fujiwara Telomerase-Specific Replication-Selective Virotherapy for Human Cancer Clin. Cancer Res., January 1, 2004; 10(1): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Lanson Jr., P. L. Friedlander, P. Schwarzenberger, J. K. Kolls, and G. Wang Replication of an Adenoviral Vector Controlled by the Human Telomerase Reverse Transcriptase Promoter Causes Tumor-Selective Tumor Lysis Cancer Res., November 15, 2003; 63(22): 7936 - 7941. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
